ClinicalTrials.gg
Enrolling by invitationNCT06863909Updated Apr 8, 2026

Study on the Effectiveness of Journaling as an add-on to Cognitive Behavioral Therapy

An interventional study of Journaling and Treatment as Usual (TAU) in Affective Disorders, Rumination and Childhood Trauma, sponsored by University Hospital Tuebingen. Enrolling by invitation at 1 site in Germany. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-04-08.

Sponsored by University Hospital Tuebingen · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The aim of the present study is to examine the effects of keeping a therapy journal (journaling) on the effectiveness of cognitive behavioral therapy (CBT). Homework assignments are a fundamental component of behavioral therapies. In line with the learning theory foundation of behavioral therapies, various types of homework are used to facilitate learning processes between therapy sessions and to enable patients to make progress. One way to enhance individual goal setting and reflection in patients is through the use of "therapy journals."

The goal of the planned project is to evaluate the effectiveness of goal-oriented journal writing as an additional element in cognitive behavioral therapy (CBT). To do this, psychotherapy patients will be randomly assigned to two treatment groups: CBT vs. CBT + Journaling. Patients will be block-randomized until 40 patients have completed the study in each treatment arm (at least 10 completed sessions).

Read the detailed description

As part of this study, the investigators are examining the effectiveness of certain therapeutic techniques that could improve the effectiveness of psychotherapy. Patients will be assigned to one of two treatment groups: one group will receive standard treatment, while the second group will receive additional tasks/techniques. Patients will be block-randomized until 40 patients have completed the study in each treatment arm (at least 10 completed sessions). The study will span a period of 24 sessions (short-term psychotherapy KZT1\&2), during which the severity of their symptoms will be assessed at the beginning of each session (duration approx. 2 minutes). Additionally, participants will be asked to answer some questions about basic documentation (diagnoses, symptoms) at the beginning and end of the study (duration approx. 20 minutes).

The investigators assure that the personal data they collect will be protected in accordance with the European Data Protection Regulation. Collected data will only be analyzed in anonymized form, meaning without mentioning any names, and may be published in scientific journals. All data will be stored in encrypted form using personal codes. All data will be digitally archived for a period of 10 years on a well-secured drive at the University Hospital Tübingen; only the study leaders (Dr. Rosenbaum and Dr. Ehlis) are authorized to re-identify the data. The investigators would like to inform that the collected data will not be used for diagnostic purposes regarding possible pathological changes. There are no health risks associated with this study, and while it is unlikely to benefit personally from it, the participation will contribute to scientific knowledge.

02

Conditions studied

  • Affective Disorders
  • Rumination
  • Childhood Trauma
  • Eating Disorder
  • Substance Use Disorder
  • Personality Disorder
  • Mental Disorder
03

In context

Mood Disorders

561 studies on the registry are indexed under Mood Disorders; 105 are open to participants now.

This study's planned enrollment of 80 is close to the median of 80 across 419 interventional studies indexed under Mood Disorders.

Browse Mood Disorders studies →

Lead sponsor

University Hospital Tuebingen is the lead sponsor of 490 studies on the registry; 108 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients in ambulant cognitive behavioral therapy

Exclusion criteria

Exclusion Criteria:

  • none
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Active comparator
    Treatment as usual

    Behavioral: Treatment as Usual (TAU)

  • Experimental
    Treatment as usual + Journaling

    Behavioral: Journaling · Behavioral: Treatment as Usual (TAU)

Interventions

  • BehavioralJournaling

    In the journaling condition, participants will be asked to keep a therapy journal twice a day in addition to the content of the cognitve behavioral therapy. At the beginning of the day, patients are to set a daily goal that aligns with their therapy goals (e.g., remaining calm when negative thoughts arise), and at the end of the day, they will reflect on the day itself and the work done on their therapy goals.

  • BehavioralTreatment as Usual (TAU)

    Patients in this arm receive standard treatment (cognitive behavioral therapy) for their individual diagnosis. The study participation spans a period of 24 sessions (short-term psychotherapy KZT1\&2), during which the severity of symptoms will be assessed at the beginning of each session (duration approx. 2 minutes). Additionally, participants will be asked to answer some questions about basic documentation (diagnoses, symptoms) at the beginning and end of the study (duration approx. 20 minutes).

06

What researchers measure

Primary outcomes

  1. Questionnaire for the Evaluation of Psychotherapy Progress (german: Fragebogen zur Evaluation von Psychotherapieverläufen (english translation: Questionnaire for evaluating the course of psychotherapy) (FEP-2))

    Number of patients exhibiting reliable changes in FEP-2 scores between baseline and end of treatment. FEP-2 = Fragebogen zur Evaluation von Psychotherapieverläufen (english translation: Questionnaire for evaluating the course of psychotherapy). Minimum = 1; Maximum = 5. Higher scores mean a better outcome.

    Time frame: From enrollment to the end of treatment at 24 weeks

  2. Questionnaire for the Evaluation of Psychotherapy Progress (german: Fragebogen zur Evaluation von Psychotherapieverläufen (english translation: Questionnaire for evaluating the course of psychotherapy)(FEP-2))

    Number of sessions until patients exhibit reliable changes in FEP-2 scores between baseline and end of treatment. FEP-2 = Fragebogen zur Evaluation von Psychotherapieverläufen (english translation: Questionnaire for evaluating the course of psychotherapy). Minimum = 1; Maximum = 5. Higher scores mean a better outcome.

    Time frame: From enrollment to the end of treatment at 24 weeks

  3. Questionnaire for the Evaluation of Psychotherapy Progress (german: Fragebogen zur Evaluation von Psychotherapieverläufen (english translation: Questionnaire for evaluating the course of psychotherapy)(FEP-2))

    Investigation of the changes in FEP-2 scores between the groups between baseline and end of treatment. FEP-2 = Fragebogen zur Evaluation von Psychotherapieverläufen (english translation: Questionnaire for evaluating the course of psychotherapy). Minimum = 1; Maximum = 5. Higher scores mean a better outcome.

    Time frame: From enrollment to the end of treatment at 24 weeks

  4. Questionnaire for the Evaluation of Psychotherapy Progress (german: Fragebogen zur Evaluation von Psychotherapieverläufen (english translation: Questionnaire for evaluating the course of psychotherapy)(FEP-2))

    Investigation of a repeated-measures ANOVA to compare the mean FEP2 values (intent-to-treat; last observation carried forward) across different phases: baseline (sessions 1-5), early change (sessions 6-15), and late change (sessions 15-25). FEP-2 = Fragebogen zur Evaluation von Psychotherapieverläufen (english translation: Questionnaire for evaluating the course of psychotherapy). Minimum = 1; Maximum = 5. Higher scores mean a better outcome.

    Time frame: From enrollment to the end of treatment at 24 weeks

Secondary outcomes

  1. Number of days patients completed the diary

    At the end of each therapy session, the therapist assesses the frequency with which the diary was completed as an indicator of the complicance of the patient. The "frequency of completion" is measured in the number of days in which the diary was completed (e.g. diary was completed on 5 days = 5). The maximum of the scale is calculated by the number of days that have passed since the last session. Higher scores mean a better outcome.

    Time frame: From enrollment to the end of treatment at 24 weeks

  2. Custom questionnaire: Quality of implementation of goals

    At the end of each therapy session, the therapist rates the quality of the implementation of the goals as an indicator of the compliance of the patient. The scale "Quality of implementation of goals" is measured on a custom 5-point Likert scale. The therapist rates: 1. = did not implement the rules of goal setting on any day 2. = implemented the rules of goal setting on less than half of the days, but not never 3. = implemented the rules of goal setting on half of the days 4. = implemented the rules of goal setting on more than half of the days, but not always 5. = implemented the rules of goal setting every day The minimum is correspondingly 1, the maximum 5. Higher scores mean a better outcome.

    Time frame: From enrollment to the end of treatment at 24 weeks

  3. Custom questionnaire: Quality of reflection

    At the end of each therapy session, the therapist rates the quality of the reflection as an indicator of the compliance of the patient. The scale "Quality of reflection" is measured on a custom 5-point Likert scale. The therapist rates: 1. = not reflected on any day if necessary 2. = reflected on less than half of the days, but not never, if necessary 3. = reflected on half of the days if necessary 4. = reflected on more than half of the days, but not always, if necessary 5. = reflected on every day if necessary The minimum is correspondingly 1, the maximum 5. Higher scores mean a better outcome.

    Time frame: From enrollment to the end of treatment at 24 weeks

  4. Custom questionnaire: Quality and quantity of homework completion

    At the end of each therapy session, the therapist rates the quality of the overall quality and quantity of the homework completion. This scale is measured on a custom 5-point Likert scale. The therapist rates: 1. = not at all 2. = a little 3. = moderate 4. = good 5. = very good The minimum is correspondingly 1, the maximum 5. Higher scores mean a better outcome.

    Time frame: From enrollment to the end of treatment at 24 weeks

07

Study locations

1 site
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06863909
Responsible party
Sponsor
First posted
Mar 7, 2025
Start date
Nov 20, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Apr 8, 2026

Study contacts

Ann-Christine Ehlis, Dr.
principal investigator · University Hospital Tübingen Department of Psychiatry and Psychotherapy

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion